CRMD

CorMedix Stock Price

5.85
0.18 (3.17%)
Upgrade to Real-Time
Afterhours (Closed)
5.85
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
CorMedix Inc CRMD AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.18 3.17% 5.85 17:08:58
Close Price Low Price High Price Open Price Previous Close
5.85 5.65 5.86 5.76 5.67
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,015 129,820 $ 5.75 $ 746,183 486,422 2.00 - 7.97
Last Trade Time Type Quantity Stock Price Currency
20:00:00 8,060 $ 5.85 USD

CorMedix Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 182.75M 31.24M 30.67M $ 283.27k $ - -1.78 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
3.57M $ - 0.00% 153.07k 12.20%

more financials information »

CorMedix News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRMD Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week5.775.985.52025.72138,6540.081.39%
1 Month5.186.255.105.86299,6260.6712.93%
3 Months4.766.253.805.04480,7911.0922.9%
6 Months4.097.573.475.11379,6791.7643.03%
1 Year6.067.972.005.25320,170-0.21-3.47%
3 Years3.089513.700.86055.141,363,7752.7689.35%
5 Years11.1022.700.86055.47999,198-5.25-47.3%

CorMedix Description

Cormedix Inc is a biopharmaceutical company which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution or the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology. The Neutrolin product is designed to target unmet medical need.


Your Recent History
AMEX
CRMD
CorMedix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.